In This Section
I-123 MIBG
I-123-metaiodobenzylguanidine (MIBG) with iodine-123, known as I-123-MIBG scintigraphy, is an imaging test used to detect neuroendocrine tumors. These abnormal masses of tissue arise from the cells of the endocrine (or hormonal) and nervoussystems. Many are benign, while some are malignant. They most commonly occur in the intestine, but are also found in the lung and the rest of the body.
The procedure involves the injection of the radiotracer I-123-MIBG into the patient’s bloodstream and imaging with a gamma camera or SPECT. It is used to:
- confirm suspected tumors in neuroendocrine tissue
- determine if the cancer has spread elsewhere in the body
- evaluate a tumor‘s response to therapy.